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Abstract
Insulin receptor substrate (IRS)-1 is a key protein in insulin signaling. Several studies have shown that the expression of IRS-1 can be
modulated by protein degradation via the proteasome and the degradation of IRS-1 can be related to insulin-resistant states. The deg-
radation of IRS-1 has been shown to be induced by SOCS-1 and SOCS-3 via the ubiquitin pathway. The goal of our study was to deter-
mine if the induction of SOCS-3 correlated with increased IRS-1 degradation in cultured 3T3-L1 adipocytes. Interestingly, our studies
have shown that there is little correlation between the induction in SOCS-3 expression and the degradation of IRS-1 in mature 3T3-L1
adipocytes. Our results clearly demonstrate that treatment with leukemia inhibitory factor (LIF) or cardiotrophin (CT)-1 strongly induc-
es the expression of SOCS-3 in mature 3T3-L1 adipocytes, but does not affect the degradation of IRS-1. On the contrary, tumor necrosis
factor (TNF) a and insulin, which very weakly induce SOCS-3 expression, have profound effects on IRS-1 degradation. In summary, our
results indicate that the expression of SOCS-3 does not correlate with the degradation of IRS-1 proteins in fat cells.
 2006 Elsevier Inc. All rights reserved.
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Insulin receptor substrates (IRS proteins) are a family of
proteins that function as mediators in insulin signaling
pathways. IRS proteins are phosphorylated by insulin
receptors after the binding of insulin, and phosphorylated
IRS proteins recruit various Src homology 2 (SH2) pro-
teins, including phosphatidylinositol 3-kinase (PI3K),
Grb2, and SHP2, Fyn, Nyk (reviewed in [1–3]). Following
the activation of these proteins, multiple signaling path-
ways are induced and cellular responses include changes
in glucose uptake, glycogen synthesis, mitogenesis, or gene
expression [4]. A variety of studies have demonstrated a
role for IRS-1 in somatic growth, insulin action, and
glucose metabolism and insulin resistance [5]. The cellular
levels of IRS-1 are affected by many effectors including
growth factors and cytokines. In the last several years,
many independent studies have revealed that the loss of
IRS-1 protein levels is due to enhanced degradation by
the ubiquitin proteasome system [6–8]. PI3K has been
shown to play a role in IRS-1 degradation [9,10] and more
recent studies suggest that b-arrestin affects IRS-1 degrada-
tion and insulin resistance [11]. Also, two members of the
SOCS family of proteins, SOCS-1 and 3, have been shown
to target IRS-1 for ubiquitin mediated degradation [12].
This observation is supported by an additional study which
demonstrated that adenoviral mediated expression of
SOCS-3 in the liver induces insulin resistance [13]. Hence,
several studies indicate that IRS-1 ubiquitin mediated deg-
radation can be conferred by an induction in SOCS-3
expression.
SOCS proteins comprise a family of suppressors of cyto-
kine signaling. Each of the family members has an SH2
domain and a conserved C-terminal SOCS box [14]. The
expression of CIS SOCS-1, SOCS-2, and SOCS-3 is
induced by various cytokines and overexpression studies
in various cell lines have demonstrated an inhibitory role
of these proteins. One member of the SOCS family has
been reported to act as a negative regulator of insulin
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signaling pathways [15]. Also, in adipose tissue of obese
mice, the treatment of TNFa induces SOCS-3 expression
[16]. It was suggested that SOCS-3 inhibits insulin signaling
pathway through the inhibition of the IRS-1 tyrosine phos-
phorylation and the association of IRS-1 with PI3K sub-
unit P85 [16], and through proteasome-mediated IRS-1
degradation [12]. However, whether SOCS-3 expression is
sufficient to induce IRS-1 degradation in 3T3-L1 adipo-
cytes has not been established. In our studies, we have
shown that both LIF and CT-1 strongly induce SOCS-3
expression in 3T3-L1 adipocytes, while TNFa and insulin
have moderate effect or almost no effect on SOCS-3 levels.
On the contrary, the levels of IRS-1 protein in LIF and
CT-1 treated cell groups are comparable to those of
untreated adipocytes, whereas IRS-1 levels in TNFa and
insulin treated cells are actively degraded. In summary,
we have clearly shown that the induction of SOCS-3 does
not correlate with the degradation of IRS-1 proteins in
3T3-L1 adipocytes. These studies indicate that the SOCS-
3 expression alone is insufficient to confer IRS-1 degrada-
tion in cultured fat cells.
Materials and methods
Materials. Dulbecco’s modified Eagle’s medium (DMEM) was
purchased from Life Technologies. Bovine and fetal bovine (FBS) sera
were purchased from Sigma and Invitrogen, respectively. Porcine growth
hormone, insulin, and cycloheximide were purchased from Sigma. Human
recombinant CT-1 was purchased from Calbiochem. Mouse recombinant
LIF was purchased from Chemicon International. The highly phospho-
specific polyclonal antibodies for STAT3 (Y705) and STAT5 (Y694) were
IgGs purchased from BD Transduction Laboratories and Upstate
Biotechnology, Active ERK antibody was a rabbit polyclonal IgG
purchased from Cell Signaling Technology. ERK1 was a rabbit polyclonal
IgGs purchased from Santa Cruz. IRS polyclonal antibody was purchased
from Santa Cruz. HRP-conjugated secondary antibodies were purchased
from Jackson Immunoresearch. Enhanced chemiluminescence (ECL) kit
was purchased from Pierce. Nitrocellulose and Zeta Probe-GT membranes
were purchased from Bio-Rad.
Cell culture. Murine 3T3-L1 preadipocytes were plated and grown to 2
days post confluence in DMEM with 10% bovine serum. Medium was
changed every 48 h. Cells were induced to differentiate by changing the
medium to DMEM containing 10% fetal bovine serum, 0.5 mM 3-isobutyl-
1-methylxanthine, 1 lM dexamethasone, and 1.7 lM insulin. After 48 h,
this medium was replaced with DMEM supplemented with 10% FBS, and
cells were maintained in this medium until utilized for experimentation.
Preparation of whole cell extracts. Monolayers of 3T3-L1 preadipo-
cytes or adipocytes were rinsed with phosphate-buffered saline (PBS) and
then harvested in a non-denaturing buffer containing 150 mM NaCl,
10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton-X 100, 0.5%
Igepal CA-630 (Nonidet P-40), 1 lM PMSF, 1 lM pepstatin, 50 trypsin
inhibitory milliunits of aprotinin, 10 lM leupeptin, and 2 mM sodium
vanadate. Samples were extracted for 30 min on ice and centrifuged at
13,000 rpm at 4 C for 10 min. Supernatants containing whole cell extracts
were analyzed for protein content using a BCA kit (Pierce) according to
the manufacturer’s instructions.
Gel electrophoresis and Western blot analysis. Proteins were separated
in 7.5% polyacrylamide (acrylamide from National Diagnostics) gels
containing sodium dodecyl sulfate (SDS) according to Laemmli [17] and
transferred to nitrocellulose membrane in 25 mM Tris, 192 mM glycine,
and 20% methanol. Following transfer, the membrane was blocked in 4%
fat-free milk for 1 h at room temperature. Results were visualized with
HRP-conjugated secondary antibodies and enhanced chemiluminescence.
RNA analysis. Total RNA was isolated from cell monolayers with
Trizol according to manufacturer’s instructions with minor modifications.
For Northern blot analysis, 20 lg of total RNA was denatured in
formamide and electrophoresed through a formaldehyde/agarose gel. The
RNA was transferred to Zeta Probe-GT, cross-linked, hybridized, and
washed as previously described [18]. SOCS-3 cDNA was labeled by
random priming using the Klenow fragment and [a 32P]dATP.
Results
SOCS-3 expression is significantly induced by LIF and
CT-1, while TNFa and insulin have distinct effects on the
induction of SOCS-3 expression
Mature 3T3-L1 adipocytes were exposed to TNFa, LIF,
GH, CT-1, or insulin. Total RNA and whole cell extracts
were isolated at various times after the treatments. The
results in Fig. 1A demonstrate that SOCS-3 mRNA is
expressed at very low levels in untreated adipocytes. Howev-
er, a 1-h treatment with LIF, CT-1 or growth hormone (GH)
results in a significant induction of SOCS-3 mRNA. In
addition, a 3 h TNFa treatment results in an induction of
SOCS-3 mRNA. Only a small induction of SOCS-3
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Fig. 1. The expression of SOCS-3 is highly induced by LIF and CT-1, but
not by TNFa and insulin in 3T3-L1 adipocytes. Whole cell extracts and
total RNA were prepared from fully differentiated serum-deprived 3T3-L1
adipocytes following a 15-min treatment of TNFa (1 nM), LIF (0.2 nM),
GH (125 ng/mL), CT-1 (0.2 nM), or insulin (50 nM) for the times
indicated in the figures. (A) Fifteen micrograms of total RNA was
electrophoresed, transferred to nylon, and subjected to Northern blot
analysis to examine SOCS-3 and aP2 mRNA accumulation. (B) One
hundred micrograms of each extract was separated by SDS–PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis. Each
of these figures represents an experiment independently performed three
times.
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The levels of aP2 RNA were not changed by the hormone/
cytokine treatments. The levels of 28S and 18S rRNA are
shown to indicate even loading of total RNA. An analysis
of SOCS-3 protein levels in this experiment revealed that
LIF and CT-1 highly induce the expression of this protein
at both 2 and 3 h following treatment. However, there was
little induction of SOCS-3 protein following TNFa, GH, or
insulin treatment. These observations are consistent with
the Northern blot analysis which demonstrates that GH
did not induce SOCS-3 mRNA to the same extent as
CT-1 and LIF.
TNFa and insulin induce IRS-1 degradation, but potent
SOCS-3 activators do not induce IRS-1 degradation
To examine the efficacy of each hormone and cytokine
studied, the cells were stimulated for 15 min and the activa-
tion of MAPK (ERKs 1 and 2) and STATs was examined
using phospho-specific antibodies. As shown in Fig. 2A, all
of the treatments resulted in the phosphorylation of
MAPK. Only the untreated () cells had minimal levels
of active MAPK which was not due to alterations in
ERK1 expression. These results are consistent with numer-
ous published studies. The results in Fig. 2A also demon-
strate that LIF, CT-1, and GH resulted in the
phosphorylation of STATs 3 and 5 under conditions where
STAT expression did not change (data not shown).
Cells from this experiment were also used to examine
IRS-1 degradation. Following a 2-h stimulation with the
hormones/cytokine, the adipocytes were treated with cyclo-
heximide to inhibit protein synthesis. We waited for 2 h
after growth factor stimulation prior to adding the cyclo-
heximide (CH) to allow for the induction in SOCS-3 pro-
tein expression which requires transcription and
translation. Following the addition of the cycloheximide,
whole cell extracts were isolated at various times to exam-
ine the decay of IRS-1 proteins. The results in Fig. 2B
clearly demonstrate that IRS-1 is a very stable protein. Fol-
lowing a 10-h treatment of cycloheximide, the control cells
or those treated with LIF, CT-1, or GH did not have any
loss of IRS-1 protein. However, cells that were treated with
either insulin or TNFa had a significant increase in decay
of IRS-1 protein.
Discussion
High expression levels of SOCS-3 have been shown to be
controlled by activation of STAT3 in cutaneous T cell lym-
phoma cells [19]. Independent studies on mouse embryonic
fibroblasts also revealed the interferon gamma induced
SOCS-3 expression is mediated by STAT3 [20]. In our stud-
ies, we also observed that SOCS-3 expression was tightly
correlated with STAT3 activation in 3T3-L1 adipocytes.
Two gp130 cytokines, LIF and CT-1, strongly induced
STAT3 phosphorylation, and correlated with a substantial
induction of SOCS-3 levels. Whereas, insulin and TNFa,
which do not induce STAT3 tyrosine phosphorylation,
had minimal effects on SOCS-3 levels under physiological
conditions (Fig. 1B).
A decrease of IRS-1 protein levels has been observed in
conditions of TNFa and insulin induced insulin resistance
in vitro and in vivo [21–23]. Recent studies indicate that
SOCS-3 plays a role in IRS-1 degradation and insulin resis-
tance. There is evidence to suggest that the expression of
SOCS-3 plays a negative role in insulin signaling by inhib-
iting IRS-1 tyrosine phosphorylation and its association
with PI3K [16], and by proteasome-mediated IRS-1 degra-
dation [12]. However, our studies have shown that two
physiological stimulators of SOCS-3 do not modulate the
turnover of IRS-1 proteins in adipocytes (Fig. 2B). Howev-





















Fig. 2. The degradation of IRS-1 is induced by TNFa and insulin, but not
by potent inducers of SOCS-3 expression in 3T3-L1 adipocytes. (A) Whole
cell extracts were isolated from serum deprived mature 3T3-L1 adipocytes
that were treated with TNFa, LIF, GH, CT-1, or insulin at the doses
indicated in the previous figures. One hundred micrograms of each extract
was separated by SDS–PAGE, transferred to nitrocellulose, and subjected
to Western blot analysis. (B) Mature 3T3-L1 adipocytes were maintained
overnight in 2% FBS and DMEM, and were treated the following day
with TNFa, LIF, GH, CT-1, or insulin as previously described. Two hours
after growth factor treatment, the cells were treated with 50 lM
cycloheximide and were harvested at the indicated time points after
growth factor stimulation. One hundred micrograms of each extract was
separated by SDS–PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. Each of these figures represents an experiment
independently performed three times.
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er, we did observe the ability of both TNFa and insulin to
substantially increase the turnover of IRS-1 proteins that
was not accompanied by a substantial induction in
SOCS-3 expression.
The results of our study conflict with reports which sug-
gest that SOCS-3 induces IRS-1 degradation in transfected
HEK293 cells [12]. A possible explanation for these obser-
vations is that the ectopic expression of SOCS-3 in trans-
fected HEK293 cells is not physiological and, thus,
induces IRS-1 protein degradation in a non-specific man-
ner. The levels of SOCS-3 induced in cultured 3T3-L1 adi-
pocytes by cytokine treatments appear to be much less than
the levels of SOCS-3 expression that have been achieved in
transfected cells. Although, our results indicate that SOCS-
3 is not involved in IRS-1 degradation under the conditions
investigated, we cannot rule out the involvement of other
SOCS proteins.
In summary, our studies have shown that the IRS-1 deg-
radation in 3T3-L1 adipocytes is induced by insulin and
TNFa treatment, while the strong induction of SOCS-3
by LIF and CT-1 had no affect on IRS-1 degradation.
Overall, our studies suggest that the induction of SOCS-3
is insufficient to induce IRS-1 degradation in 3T3-L1
adipocytes.
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